November 18, 2026
Health news, explained with evidence
LIVE
Preventive Services Task Force Resumes Meetings Under New Leadership Blood-Based Genetic Signature May Predict CAR T-Cell Therapy Success in Lymphoma Ultraprocessed Diets May Impact Brain Reward Systems in Younger Adults Addressing Body Image and the Reality of Gluteal Anatomy Migraine and Smoking Linked to Increased Early Stroke Risk in Women CBD Oil Found Ineffective for Managing Behavioral Issues in Youths with Intellectual Disabilities Expert Advice on Hydration Gear Sparks Debate Among Recreational Runners A Structured Approach to Beginning a Strength and Cardio Routine The Role of Daily Mobility Training in Managing Sedentary Tension New Theoretical Framework Explores Memory Formation and Dementia Preventive Services Task Force Resumes Meetings Under New Leadership Blood-Based Genetic Signature May Predict CAR T-Cell Therapy Success in Lymphoma Ultraprocessed Diets May Impact Brain Reward Systems in Younger Adults Addressing Body Image and the Reality of Gluteal Anatomy Migraine and Smoking Linked to Increased Early Stroke Risk in Women CBD Oil Found Ineffective for Managing Behavioral Issues in Youths with Intellectual Disabilities Expert Advice on Hydration Gear Sparks Debate Among Recreational Runners A Structured Approach to Beginning a Strength and Cardio Routine The Role of Daily Mobility Training in Managing Sedentary Tension New Theoretical Framework Explores Memory Formation and Dementia

Pediatric Brain Cancer Research Stalls After Federal Funding Cuts to Major Trials

🏥 Public Health 2 min read 👁 10

The termination of a key National Cancer Institute consortium has paused critical clinical trials for diffuse intrinsic pontine glioma (D.I.P.G.), a devastating and nearly always fatal childhood brain tumor.

Pediatric Brain Cancer Research Stalls After Federal Funding Cuts to Major Trials🏥Public Health

Photo: The New York Times Health

Key points

  • Federal funding cuts halted the Pediatric Brain Tumor Consortium, pausing eight clinical trials.
  • D.I.P.G. is an incurable pediatric brainstem tumor with an average survival time of under a year.
  • The defunding affected trials testing immunotherapies, vaccines, and electrical skull caps.

Diffuse intrinsic pontine glioma, or D.I.P.G., is an inoperable brainstem tumor that primarily affects children between the ages of 4 and 10, with roughly 300 diagnoses annually in the United States. The disease typically leaves patients with a life expectancy of nine to 12 months following diagnosis, as there is currently no standard of care or proven cure once radiation therapy concludes. Families facing this grim prognosis often turn to clinical trials as their only remaining option to extend or save their child's life.

However, recent shifts in federal research funding have disrupted these avenues of hope. In August 2025, the National Cancer Institute opted not to renew the $4 million annual grant for the Pediatric Brain Tumor Consortium, which had served as a cornerstone of government-backed pediatric brain cancer research. The decision led to the closure or pausing of eight ongoing trials across 16 elite participating hospitals. Among the affected research were early-stage studies investigating novel immunotherapies, specialized vaccines, laser treatments, and a cranial device delivering electrical stimulation to the brain.

While officials described the move as a consolidation aimed at improving efficiencies, the sudden halt has forced families to scramble for alternative treatments, such as the Phase 2 TarGeT-A trial at Nationwide Children's Hospital in Columbus, Ohio. Experts note that observational impacts on drug development and trial accessibility can severely delay future therapeutic breakthroughs for rare and aggressive pediatric cancers. What to know: D.I.P.G. trials remain limited, and families should consult pediatric oncologists and specialized advocacy networks to navigate experimental treatment options.

Source The New York Times Health — nytimes.com/2026/11/15/well/research-stalls-for-a-year-into-a-cance… ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.